Cardio Diagnostics Holdings Inc. has announced a new clinical study in collaboration with AGEPHA Pharma to investigate a precision-guided approach to managing inflammation-driven coronary heart disease $(CHD)$. AGEPHA Pharma will provide LODOCO® (low-dose colchicine), an FDA-approved anti-inflammatory medication, for the study. The research will utilize Cardio Diagnostics' PrecisionCHD™ blood test to identify patients with inflammation-driven CHD and evaluate their response to LODOCO® over time. The study aims to use DNA methylation signatures to monitor changes in inflammation. Cardio Diagnostics is currently in the process of selecting clinical sites for the study, which will be registered as a clinical trial. Results of the study have not yet been presented and will be shared in the future upon completion of the trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.